Alirocumab for Stabilisation of Symptomatic Vulnerable Carotid Plaque

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 280 participants.

Also called NCT07586540

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 280 participants (planned count) (from the registry)
Sponsor
Middle East North Africa Stroke and Interventional Neurotherapies Organization (from the registry)
Registry
  • NCT NCT07586540
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Egypt, Jordan, Morocco, Pakistan, Qatar, Saudi Arabia, Tunisia, Türkiye (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07586540. Randomized; triple masking; primary purpose treatment. Start 2026-01-06 (actual); primary completion 2030-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Alirocumab for Stabilisation of Symptomatic Vulnerable Carotid Plaque
Acronym
CAROTID-STABIL
Condition
Carotid Stenosis
Intervention (Drug)
Alirocumab
Intervention (Drug)
Placebo
Intervention (Drug)
Atorvastatin
Lead sponsor
Middle East North Africa Stroke and Interventional Neurotherapies Organization (class: other)

Record details

Record id
cardio:ct-nct07586540
Content hash
cc5314ea7b90162c1c8d032c6cdadde6af2fd061727d5d7a3021e818bf2c5a6e